Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543635 | NSE: PPLPHARMA

NSE BSE
157.99
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  157.35
  •  159.25
  •  157.13
  •  157.36
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2485293
  •  3935.76
  •  307.90
  •  114.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,606.78
  • 733.50
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 36,851.86
  • 0.04%
  • 4.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.95%
  • 1.25%
  • 13.29%
  • FII
  • DII
  • Others
  • 31.73%
  • 13.43%
  • 5.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 7.60

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 4.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -63.81

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
2,241.75
1,911.38
17.28%
1,951.14
1,748.85
11.57%
2,552.36
2,163.58
17.97%
1,958.57
1,715.97
14.14%
Expenses
1,900.14
1,645.74
15.46%
1,746.65
1,616.53
8.05%
2,022.43
1,812.31
11.59%
1,690.20
1,628.64
3.78%
EBITDA
341.61
265.64
28.60%
204.49
132.32
54.54%
529.93
351.27
50.86%
268.37
87.33
207.31%
EBIDTM
15.24%
13.90%
10.48%
7.57%
20.76%
16.24%
13.70%
5.09%
Other Income
61.11
49.19
24.23%
19.54
38.31
-49.00%
26.38
24.50
7.67%
61.51
82.54
-25.48%
Interest
107.64
109.87
-2.03%
106.96
118.52
-9.75%
114.22
104.25
9.56%
105.88
94.65
11.86%
Depreciation
192.22
184.51
4.18%
184.55
173.61
6.30%
196.13
184.41
6.36%
186.32
164.43
13.31%
PBT
102.86
20.45
402.98%
-67.48
-121.50
-
215.44
87.11
147.32%
5.41
-89.21
-
Tax
97.53
34.54
182.37%
43.56
-8.53
-
126.21
44.78
181.84%
9.25
16.54
-44.07%
PAT
5.33
-14.09
-
-111.04
-112.97
-
89.23
42.33
110.80%
-3.84
-105.75
-
PATM
0.24%
-0.74%
-5.69%
-6.46%
3.50%
1.96%
-0.20%
-6.16%
EPS
0.17
0.04
325.00%
-0.67
-0.81
-
0.77
0.41
87.80%
0.08
-0.74
-

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
8,703.82
8,171.16
7,081.55
6,559.10
6,314.90
Net Sales Growth
15.44%
15.39%
7.97%
3.87%
 
Cost Of Goods Sold
3,160.38
2,954.00
2,703.30
2,451.26
2,059.11
Gross Profit
5,543.44
5,217.16
4,378.25
4,107.84
4,255.79
GP Margin
63.69%
63.85%
61.83%
62.63%
67.39%
Total Expenditure
7,359.42
7,000.65
6,453.31
5,609.44
4,886.94
Power & Fuel Cost
-
241.59
207.81
163.56
136.70
% Of Sales
-
2.96%
2.93%
2.49%
2.16%
Employee Cost
-
2,029.50
1,896.35
1,588.83
1,467.74
% Of Sales
-
24.84%
26.78%
24.22%
23.24%
Manufacturing Exp.
-
731.64
674.10
589.03
544.09
% Of Sales
-
8.95%
9.52%
8.98%
8.62%
General & Admin Exp.
-
542.00
472.78
428.49
367.25
% Of Sales
-
6.63%
6.68%
6.53%
5.82%
Selling & Distn. Exp.
-
359.75
372.59
317.81
247.91
% Of Sales
-
4.40%
5.26%
4.85%
3.93%
Miscellaneous Exp.
-
142.17
126.38
70.46
64.14
% Of Sales
-
1.74%
1.78%
1.07%
1.02%
EBITDA
1,344.40
1,170.51
628.24
949.66
1,427.96
EBITDA Margin
15.45%
14.32%
8.87%
14.48%
22.61%
Other Income
168.54
201.14
225.11
275.80
164.11
Interest
434.70
448.49
344.18
198.25
163.45
Depreciation
759.22
740.57
676.69
586.18
545.04
PBT
256.23
182.59
-167.52
441.03
883.58
Tax
276.55
161.47
66.31
109.02
114.02
Tax Rate
107.93%
134.78%
-38.00%
25.59%
12.64%
PAT
-20.32
17.82
-186.46
375.96
835.03
PAT before Minority Interest
-20.32
17.82
-186.46
375.96
835.03
Minority Interest
0.00
0.00
0.00
0.00
0.00
PAT Margin
-0.23%
0.22%
-2.63%
5.73%
13.22%
PAT Growth
0.00%
-
-
-54.98%
 
EPS
-0.15
0.13
-1.41
2.84
6.30

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
7,911.37
6,773.50
6,696.60
5,605.00
Share Capital
1,322.95
1,193.32
1,185.91
994.60
Total Reserves
6,560.95
5,580.18
5,510.69
4,610.30
Non-Current Liabilities
2,928.77
3,812.00
2,902.58
2,560.38
Secured Loans
2,483.75
3,383.54
2,622.14
2,339.16
Unsecured Loans
0.00
0.00
0.00
0.00
Long Term Provisions
316.45
275.97
145.34
6.78
Current Liabilities
4,457.10
3,851.04
3,118.01
2,590.70
Trade Payables
1,538.37
1,192.71
1,026.35
917.94
Other Current Liabilities
1,575.68
1,305.30
1,242.76
1,140.63
Short Term Borrowings
1,171.38
1,302.29
658.76
360.52
Short Term Provisions
171.67
50.74
190.14
171.61
Total Liabilities
15,297.24
14,436.54
12,717.19
10,756.08
Net Block
7,989.93
7,468.60
6,879.18
6,105.49
Gross Block
12,137.48
10,842.12
9,510.49
8,173.25
Accumulated Depreciation
4,147.55
3,373.52
2,631.31
2,067.76
Non Current Assets
9,744.97
9,593.07
8,565.30
7,006.96
Capital Work in Progress
1,115.80
1,418.58
1,172.34
626.65
Non Current Investment
240.26
211.87
216.77
122.67
Long Term Loans & Adv.
398.98
493.98
296.97
152.11
Other Non Current Assets
0.00
0.04
0.04
0.04
Current Assets
5,552.27
4,843.47
4,151.89
3,749.12
Current Investments
144.69
427.11
50.40
0.00
Inventories
2,175.88
1,681.37
1,388.80
1,232.00
Sundry Debtors
2,134.43
1,799.34
1,785.28
1,574.94
Cash & Bank
482.56
307.56
328.99
405.62
Other Current Assets
614.71
140.24
93.66
141.01
Short Term Loans & Adv.
532.78
487.85
504.76
395.55
Net Current Assets
1,095.17
992.43
1,033.88
1,158.42
Total Assets
15,297.24
14,436.54
12,717.19
10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
1,004.54
483.89
766.42
597.58
PBT
119.80
-160.56
441.03
639.68
Adjustment
1,275.88
1,135.53
787.10
721.99
Changes in Working Capital
-234.30
-302.08
-292.29
-619.58
Cash after chg. in Working capital
1,161.38
672.89
935.84
742.09
Interest Paid
0.00
0.00
0.00
0.00
Tax Paid
-156.84
-189.00
-169.42
-144.51
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
Cash From Investing Activity
-434.01
-1,338.78
-1,812.10
-4,479.93
Net Fixed Assets
-327.03
-350.70
-1,249.33
Net Investments
38.83
-117.46
-38.01
Others
-145.81
-870.62
-524.76
Cash from Financing Activity
-422.36
817.79
794.19
3,976.83
Net Cash Inflow / Outflow
148.17
-37.10
-251.49
94.48
Opening Cash & Equivalents
53.23
85.18
261.97
151.95
Closing Cash & Equivalent
219.19
53.23
85.18
261.97

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
59.59
55.44
55.15
56.35
ROA
0.12%
-1.37%
3.20%
7.76%
ROE
0.24%
-2.77%
6.11%
14.90%
ROCE
5.07%
1.95%
7.10%
13.06%
Fixed Asset Turnover
0.82
0.80
0.83
0.77
Receivable days
76.20
80.70
83.94
91.03
Inventory Days
74.72
69.11
65.47
71.21
Payable days
168.73
149.81
144.76
162.72
Cash Conversion Cycle
-17.80
0.00
4.65
-0.47
Total Debt/Equity
0.58
0.81
0.60
0.52
Interest Cover
1.40
0.65
3.45
6.81

Annual Reports:

FY 2024
FY 2023
FY 2022

News Update:


  • Piramal Pharma reports over 4-fold jump in Q2 consolidated net profit
    24th Oct 2024, 11:30 AM

    Consolidated total income of the company increased by 17.46% at Rs 2302.86 crore for Q2FY25

    Read More
  • Piramal Pharma - Quarterly Results
    23rd Oct 2024, 20:07 PM

    Read More
  • Piramal Pharma’s PPS business to invest $80 million to expand Kentucky facility
    1st Oct 2024, 11:58 AM

    Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches

    Read More
  • Piramal Pharma gets SBTi approval for GHG Commitment
    17th Sep 2024, 10:57 AM

    Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year

    Read More
  • Piramal Pharma to subscribe preference shares in arm against outstanding loan
    30th Aug 2024, 11:44 AM

    The Administrative Committee of the Board of Directors of the Company at its meeting held on August 30, 2024, has approved the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.